Eikon Therapeutics, Inc. (EIKN) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Eikon Therapeutics, Inc. on June 10, 2026, covering events occurring on June 5, 2026. The Company is a Delaware corporation with its principal executive offices in Millbrae, California, and its common stock trades on The Nasdaq Stock Market LLC under the symbol "EIKN". The filing addresses the appointment of a new director and associated compensatory arrangements.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. This report is limited to corporate governance and compensation disclosures.
Material Changes
The primary material change disclosed is the appointment of Ma. Fatima D. Francisco to the Board of Directors as a Class I director, effective June 15, 2026. She will serve until the 2027 annual meeting of stockholders or until a successor is elected. Ms. Francisco has been appointed to the Compensation Committee.
Compensatory Arrangements and Outlook
Ms. Francisco is eligible for the Company's 2026 non-employee director compensation program, which includes:
- Cash Retainer: An annual retainer of $50,000 for Board service, paid in equal quarterly installments and prorated based on days served.
- Stock Option Grant: An initial award of an option to purchase 85,937 shares of common stock.
- Option Terms: The exercise price is $8.96 per share (the closing price on the grant date). The option vests in 48 substantially equal monthly installments, contingent on continued service.
The filing states there are no related person transactions requiring disclosure under Item 404(a) of Regulation S-K. No specific guidance, outlook, or risk factors were disclosed in this specific filing.
Investor Verification Checklist
- Verify the effective date of Ms. Francisco's board service (June 15, 2026) and her tenure through the 2027 annual meeting.
- Confirm the vesting schedule of the 85,937 stock options (48 monthly installments) and the exercise price of $8.96.
- Review the Company's most recent 10-K or 10-Q for current financial position, as this 8-K contains no financial data.
- Check for any subsequent filings regarding the composition of the Compensation Committee.